Related Experiment Video

Updated: Feb 1, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.1K

Cancer Drug Toxicity: Moving from Patient to Survivor

Megan Slocum1, Sophie F Garcia1, June M McKoy2

  • 1Cancer Survivorship Institute, Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, IL, USA.

Cancer Treatment and Research
|December 16, 2018
PubMed

Insights

Millions of cancer survivors are living longer thanks to advancements in cancer therapies and early detection. Improved cancer pharmaceutical safety and survivorship care planning further support longevity for all cancer types.

Area of Science:

  • Oncology
  • Cancer Survivorship Research

Background:

  • Increasing number of individuals worldwide are living beyond a 5-year cancer diagnosis.
  • Cancer survivorship is a growing field influenced by medical and public health advancements.

Purpose of the Study:

  • To summarize the key factors contributing to increased cancer survivorship.
  • To highlight the impact of modern therapies and early detection on longevity.

Main Methods:

  • Review of current literature on cancer survivorship trends.
  • Analysis of factors influencing long-term cancer outcomes.

Main Results:

  • Targeted therapies and personalized medicine have significantly improved survival rates.
  • Earlier cancer diagnosis, preventive screenings, and enhanced drug safety contribute to longevity.
  • All cancer types have observed improvements in survivorship.

Conclusions:

  • Cancer survivorship is enhanced by advancements in treatment modalities and early detection.
  • Survivorship care planning and novel drug therapies are expected to further support cancer survivors.
  • The outlook for cancer survivors continues to improve due to ongoing research and healthcare initiatives.
Keywords:
CancerDrug policyPharmaceutical safetySurvivorship

More Related Videos

Whole Body Vibration Methods with Survivors of Polio04:16

Whole Body Vibration Methods with Survivors of Polio

Published on: October 17, 2018

9.2K
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

9.4K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
272
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
261
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
323